Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
- 29 April 2008
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 49 (2), 163-169
- https://doi.org/10.1016/j.jhep.2008.03.027
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CHepatology, 2007
- Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology, 2007
- Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized StudyGastroenterology, 2006
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In VivoJournal of Virology, 2000